Erlotinib in non-small cell lung cancer: a review.

FH Blackhall, S Rehman, N. Thatcher

    Research output: Contribution to journalArticlepeer-review


    Erlotinib (Tarceva, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in cancer. Patients with advanced, incurable non-small cell lung cancer (NSCLC) may derive a clinical benefit from first- and second-line chemotherapy, but third-line treatment with available cytotoxic agents is not effective. Remarkably, EGFR/HER1 antagonists have demonstrated activity as second- and even third-line treatment for this disease. Erlotinib is the first of this novel class of drug to demonstrate a statistically significant and clinically relevant difference in overall survival, progression free survival and time to disease related symptoms (cough, pain, shortness of breath) compared with treatment with best supportive care in patients who have failed standard first- or second-line chemotherapy. This paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib in NSCLC.
    Original languageEnglish
    JournalExpert Opin Pharmacother
    Volume6( 6)
    Publication statusPublished - Jun 2005


    Dive into the research topics of 'Erlotinib in non-small cell lung cancer: a review.'. Together they form a unique fingerprint.

    Cite this